3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
10
Phase 2
3
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Glioblastoma
30
Carcinoma, Non-Small-Cell Lung
30
Lung Neoplasms
23
Head and Neck Neoplasms
21
Squamous Cell Carcinoma of Head and Neck
15
Lymphoma
15
Gliosarcoma
15
Central Nervous System Neoplasms
14
Sarcoma
12
Esophageal Neoplasms
12
Rectal Neoplasms
10
Glioma
10
Leukemia
9
Breast Neoplasms
9
Brain Neoplasms
9
Prostatic Neoplasms
8
Pancreatic Neoplasms
8
Lymphoma, Follicular
7
Esophageal Squamous Cell Carcinoma
7
Neoplasms
6
Melanoma
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Uterine Cervical Neoplasms
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Neoplasm Metastasis
5
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma, B-Cell, Marginal Zone
5
Colorectal Neoplasms
5
Carcinoma, Renal Cell
5
Astrocytoma
5
Interventions
Temozolomide
8
Irinotecan
7
Vincristine
6
Nivolumab
2
temsirolimus
1
talazoparib
1
surufatinib
1
sonidegib
1
silmitasertib
1
regorafenib
1
prexasertib
1
pegylated granulocyte colony-stimulating factor
1
pegfilgrastim
1
liposomal doxorubicin
1
lenvatinib
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
irinotecan sucrosofate
1
holmium-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetrakis(methylenephosphonic acid)
1
ganitumab
1
eribulin
1
efineptakin alfa
1
dostarlimab
1
dinutuximab
1
copanlisib
1
bempegaldesleukin
1
atezolizumab
1
adavosertib
1
abemaciclib
1
Zoledronic Acid
1
Vinorelbine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Rhabdomyosarcoma
×
Radiotherapy
×
Clear all
NCT04625907
2024-05-23
FaR-RMS
University of Birmingham
Phase 1/2
Recruiting
1,672 enrolled